Best of ASCO - 2014 Annual Meeting



Acute Leukemia

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
A novel thrombopoietin mimetic RWJ-800088 increases megakaryopoiesis without causing malignant proliferation in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

Diego Andres Adrianzen Herrera


A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML).

Naval Guastad Daver


A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B-cell acute lymphoblastic leukemia (ALL).

Margaret T. Kasner


A phase I/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504.

Marc Saul Schwartz


A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.

Aref Al-Kali


A phase III trial to evaluate the efficacy of uproleselan (GMI-1271) with chemotherapy in patients with relapsed/refractory acute myeloid leukemia.

Daniel J. DeAngelo


A randomized phase II trial of CX-01 with standard therapy in elderly patients with acute myeloid leukemia (AML).

Tibor Kovacsovics


A retrospective, real-world population-based analysis of treatment patterns and outcomes in adult patients with relapsed/refractory acute myeloid leukemia in Alberta, Canada.

Michelle N. Geddes


A video decision aid to improve acute myeloid leukemia patients’ illness understanding: Results of a pilot trial.

Thomas William LeBlanc


Activity of venetoclax-based therapy in TP53-mutated acute myeloid leukemia.

Mahran Shoukier


Allogeneic hematopoietic stem cell transplantation contributes to eradication of minimal residual disease in adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with dasatinib.

Jeremy Chang


Analytical validation of a 47-gene NGS panel for molecular profiling of myeloid neoplasms.

Sun Hee Rosenthal


Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia.

Mansour Alfayez


Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.

Paul B. Koller


Bayesian network meta-analysis (NMA) of complete remission without or with incomplete hematologic recovery (CR/CRi) to CPX-351, FLAG, and standard 7+3 (7+3) chemotherapy in the treatment of newly diagnosed secondary acute myeloid leukemia (sAML).

Mok Oh


Blinatumomab is safe and effective in relapsed and MRD-positive B-ALL CD19+ patients: The Bologna Compassionate Program Experience.

Giovanni Martinelli


CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.

Farhad Ravandi


Clinical validation of long-range PCR assay for MLL partial tandem duplications for acute myeloid leukemia.

Sun Hee Rosenthal


Clinical value of event-free survival (EFS) in acute myeloid leukemia (AML).

Abhishek Maiti


Combination therapy with CpG oligodeoxynucleotide and imatinib can reverse the drug resistance when applied alone through promoting BAX activation and overcoming BCR-ABL1-independent PI3K/AKT activation.

Ling Bai


Comparison of PEG-rhG-CSF and common rhG-CSF after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Kaiqi Liu


Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.

Richard M. Stone


Does intensity of induction chemotherapy affect the impact of measurable residual disease (MRD) on prognosis in acute myeloid leukemia (AML)?

Michael Jamie Hochman


Effect of gilteritinib on survival in patients with FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) AML who have common AML co-mutations or a high FLT3-ITD allelic ratio.

Mark J. Levis


Effects of obesity on overall survival (OS) of patients with acute myeloid leukemia (AML).

Prajwal Dhakal


End of phase I results of ZUMA-3, a phase 1/2 study of KTE-X19, anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Bijal D. Shah


Evaluation of etiologic genetic polymorphisms by whole exome sequencing (WES) in the Mayo Clinic AML epidemiology cohort (MCAEC).

Zaid Abdel Rahman


Evaluation of prognostic factors after induction therapy in AML.

Craig E. Devoe


First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.

Sonja Loges


Granulocyte transfusions in patients with skin and soft tissues infections and leukemia: Are they useful?

Yamil Michelen


Identifying Mcl-1 protein dependencies using dimerization-specific antibody biomarker for predicting response to targeted apoptosis inducing therapies.

Michael H. Cardone


IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study.

Hussein Abbas


Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia.

Iman Aboudalle


Incidence, characteristics, and risk factors of venous thromboembolism in adolescent and young adult acute lymphoblastic leukemia patients receiving peg-asparaginase.

Brynne Underwood


In-hospital mortality in acute promyelocytic leukemia patients: A study of national inpatient sample.

Dipesh Uprety


Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.

Hagop M. Kantarjian


Interim results from a phase Ib/II clinical study of the glutaminase inhibitor telaglenastat (CB-839) in combination with azacitidine in patients with advanced myelodysplastic syndrome (MDS).

Veronica Guerra


Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.

Gail J. Roboz


Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.

B. Douglas Smith


Mechanism of biologic therapy for pre B-cell acute lymphoblastic leukemia with CRLF2 overexpression.

WayAnne Watson


MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.

Pau Montesinos


Mortality of acute promyelocytic leukemia in a rural tertiary care center.

Joseph Vadakara


Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).

Courtney Denton Dinardo


Nonclinical safety assessment of AMG 553, an investigational anti-FLT3 CAR-T therapy.

Christine M Karbowski


Outcomes with CPX-351 versus 7+3 by baseline bone marrow (BM) blast percentage in older adults with newly diagnosed high-risk/secondary acute myeloid leukemia (sAML).

Ellen K. Ritchie


Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.

Elias Jabbour


Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.

Jessica Hochberg


Phase II trial of CPX-351 (cytarabine:daunorubicin) liposome injection in patients with acute myeloid leukemia >60 years of age who have not been treated with intensive chemotherapy.

Ellen K. Ritchie


Real-world treatment patterns in adult patients (pts) with B-cell precursor acute lymphoblastic leukemia (BCP ALL) in first hematologic complete remission (CR1) with and without minimal residual disease (MRD).

Shweta Shah


Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.

Olatoyosi Odenike


Role of IL27 and IL35 as biomarkers and potential targets in acute myeloid leukemia.

Heba A. Ahmed


Safety and efficacy of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: An updated analysis.

Amanda Cecile Przespolewski


Safety and feasibility of outpatient high-dose cytarabine (HIDAC) and intermediate-dose cytarabine (IDAC) for consolidation therapy in acute myeloid leukemia (AML).

Wenhui Li


Survival outcomes in patients with good risk acute myeloid leukemia: A single-center retrospective review.

Kathryn Bower


The bone marrow stroma capacity to confer resistance to leukemia cells from Ara-C treatment as a prognostic factor for overall survival in AML.

Patricia Macanas-Pirard


The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

David Andrew Sallman


The impact of infection on health-related quality of life (HRQoL) in patients with Philadelphia negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (Ph- R/R BCP ALL) in a randomized, open-label, phase 3 study (TOWER).

Andre C. Schuh


The prognosis of NF1 mutations in newly diagnosed AML: A single-center retrospective study.

Mohammad Telfah


Time from randomization to first subsequent induction/salvage therapy (ST) in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) treated with inotuzumab ozogamicin (InO) in the phase 3 INO-VATE trial.

Elias Jabbour


Timed sequential therapy with high-dose cytarabine and mitoxantrone as an induction regimen for acute myeloid leukemia: An update on adverse events.

Kristin J. Richardson


Treatment with FLAG followed by second allogeneic stem cell transplant for relapsed acute myeloid leukemia and myelodysplastic syndrome.

Brian Pham


Venetoclax (VEN) and tyrosine kinase inhibitor (TKI) combinations in Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML MBP).

Abhishek Maiti